Cullum, Christopher Kjaer
Do, Thien Phu
Ashina, Messoud
Bendtsen, Lars
Hugger, Sarah Sonja
Iljazi, Afrim
Gusatovic, Julia
Snellman, Josefin
Lopez-Lopez, Cristina
Ashina, Håkan
Amin, Faisal Mohammad
Article History
Received: 6 May 2022
Accepted: 20 May 2022
First Online: 2 June 2022
Declarations
:
: Christopher Kjaer Cullum reports no conflicts of interest. Thien Phu Do reports no conflicts of interest. Messoud Ashina is a consultant, speaker, or scientific advisor for AbbVie, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva and a primary investigator for ongoing AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva trials. Messoud Ashina has no ownership interest and does not own stocks of any pharmaceutical company. Messoud Ashina serves as associate editor of Cephalalgia, associate editor of the Journal of Headache and Pain, and associate editor of Brain. Lars Bendtsen has given lectures and served on the scientific advisory board for Novartis, Allergan, Teva, Lundbeck and Eli Lilly. LB has received a research grant from Novartis. Sarah Sonja Hugger reports no conflicts of interest. Afrim Iljazi reports no conflicts of interest. Julia Gusatovic reports no conflicts of interest. Josefin Snellman is an employee of Novartis Pharma AG and have Novartis shares. Christina Lopez-Lopez is an employee of Novartis Pharma AG and have Novartis shares. Håkan Ashina reports no conflicts of interest. Faisal Mohammad Amin reported receiving a grant from the American Brain Foundation and personal fees from Novartis, Eli Lilly, Teva Pharmaceuticals, and Lundbeck outside of the submitted work.